Clinical Trials

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases,...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced...

Takeda Pharmaceutical Company Limited has announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into...

InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company's lead...

Merck and Pfizer have announced that the phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of...

Nippon Chemiphar has announced that the phase-1 clinical trial of NC-2500, a novel xanthine oxidoreductase (XOR) inhibitor, was completed, indicating...

Amgen announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE study...

Takeda Pharmaceutical Company Limited announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into a...

Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced that the Phase III JAVELIN Gastric 300 trial did not meet its...

Exelixis has announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018...